Abstract
Furazano[3,4-b]quinoxaline 1-oxides indicate significant chemical reactivity and release NO fragments in their electron impact mass spectra. A series of fused furazan N-oxide derivatives were synthesized and tested in vitro as potential NO releasing agents in the presence of L- cysteine used as a thiol cofactor. The synthesized compounds were determined using cysteine as cofactor and Griess reagent. The yield in nitrite for each compound was expressed as % NO2- (mol/mol). Compound 4c showed the higher NO releasing ability among the tested furazan N-oxide derivatives. A new class of NO-donors, Furazano[3,4-b]quinoxaline 1-Oxides hybrids was developed by joining NOdonor furoxan moiety to substituted quinoxaline 1-Oxides. It seems that lipophilicity and stereochemistry of the X substitution influences the NO donating behavior.
Keywords: Nitric oxide, NO donors, furazano[3, 4-b]quinoxaline 1-Oxides, griess.
Letters in Drug Design & Discovery
Title:In vitro Study of Furazano[3,4-b]quinoxaline 1-Oxides as Potential ΝΟ Releasing Agents
Volume: 13 Issue: 5
Author(s): Kosmas I. Stoitsis, Petros Gkizis, Emmanouella Basgiouraki, John K. Gallos and Dimitra Hadjipavlou-Litina
Affiliation:
Keywords: Nitric oxide, NO donors, furazano[3, 4-b]quinoxaline 1-Oxides, griess.
Abstract: Furazano[3,4-b]quinoxaline 1-oxides indicate significant chemical reactivity and release NO fragments in their electron impact mass spectra. A series of fused furazan N-oxide derivatives were synthesized and tested in vitro as potential NO releasing agents in the presence of L- cysteine used as a thiol cofactor. The synthesized compounds were determined using cysteine as cofactor and Griess reagent. The yield in nitrite for each compound was expressed as % NO2- (mol/mol). Compound 4c showed the higher NO releasing ability among the tested furazan N-oxide derivatives. A new class of NO-donors, Furazano[3,4-b]quinoxaline 1-Oxides hybrids was developed by joining NOdonor furoxan moiety to substituted quinoxaline 1-Oxides. It seems that lipophilicity and stereochemistry of the X substitution influences the NO donating behavior.
Export Options
About this article
Cite this article as:
I. Stoitsis Kosmas, Gkizis Petros, Basgiouraki Emmanouella, K. Gallos John and Hadjipavlou-Litina Dimitra, In vitro Study of Furazano[3,4-b]quinoxaline 1-Oxides as Potential ΝΟ Releasing Agents, Letters in Drug Design & Discovery 2016; 13 (5) . https://dx.doi.org/10.2174/1570180812666150923235828
DOI https://dx.doi.org/10.2174/1570180812666150923235828 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fibromyalgia: The Prototypical Central Sensitivity Syndrome
Current Rheumatology Reviews Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology The Role of Blood-Brain Barrier Studies in the Pharmaceutical Industry
Current Drug Metabolism Pathogenesis and Treatment of Secondary Hyperparathyroidism in Dialysis Patients: The Role of Paricalcitol
Current Vascular Pharmacology Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
Current Neurovascular Research Editorial: Oxidative Stress in Pathophysiological Conditions
Current Vascular Pharmacology The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Glycoxidation of Low Density Lipoprotein in Impaired Glucose Tolerance: Implications for the Pathogenesis of Diabetic Vascular Disease
Vascular Disease Prevention (Discontinued) Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Vascular Dementia: Atherosclerosis, Cognition and Alzheimers Disease
Current Alzheimer Research Statins: Are They All the Same?
Current Drug Therapy Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets
Current Drug Targets Neural Control of Blood Pressure: Focusing on Capsaicin-Sensitive Sensory Nerves
Cardiovascular & Hematological Disorders-Drug Targets Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) How Should We Treat Hypertension and Dyslipidemia in Patients with Prediabetes?
Current Pharmaceutical Design